Dataset opportunity
Insightmedbotics — 医学影像数据集机会
Insightmedbotics 持有的中等规模医学影像数据集，可用于诊断人工智能和计算机视觉。
Score
68.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
2025年全球医学影像人工智能市场价值为18亿美元，预计在2026-2033年期间的复合年增长率为35.1%（来源：Grand View Research）。[1]
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医学影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
混合所有权 — GDPR敏感（个人身份信息审查）
Buyer persona
医疗人工智能与诊断影像公司
Insightmedbotics 持有一个独特的、多模态的医学影像数据集，该数据集整合了大量的图像集、其机器人系统的专有物联网数据以及全面的纵向医疗记录。这种影像、机器人遥测和临床数据的丰富融合，为训练和验证具有高上下文准确性的稳健诊断人工智能模型提供了卓越的基础。
该资产的商业价值巨大，直接面向全球医学影像人工智能市场，该市场在2025年的估值为18亿美元，预计将以35.1%的复合年增长率扩张。[1] 虽然访问受到严格的隐私法规和共享所有权协议的约束，但该数据集独特的构成使其成为一个稀有且极具价值的资源，适合旨在快速增长的市场中开发下一代人工智能解决方案的买家。⚠ 尽职调查（有价值的数据，可协商的访问权限）：医疗数据受严格的医疗保健隐私法规（HIPAA/PHIPA/GDPR）管辖；临床数据所有权可能与研究医院（耶鲁大学、福克斯蔡斯癌症中心）共享；专有机器人遥测和空间映射数据高度专业化 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Insightmedbotics 拥有专有的高分辨率MRI图像数据集，该数据集直接关联到前列腺癌和乳腺癌的机器人活检手术。在预计每年增长超过35%的市场中，这种独特、FDA批准的上下文数据为构建和验证高度准确、具有商业可行性的模型提供了所需的基本真相。
See dimension details ↓- Dataset Specificity90
主导的“医疗记录”，医疗保健行业，3种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家对高质量、多模态医疗数据的需求极高，这得益于诊断人工智能市场的爆炸式增长，该市场预计复合年增长率为35.1%。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3种证据类型，3次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
所有权=混合，许可=GDPR敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2个数据需求信号（2种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，5个近期外部信号 — 已货币化的专有数据之外的数据
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — 该公司的核心业务是销售MRI兼容的机器人手术系统，而不是数据，因此，它能够通过其设备在临床环境中的使用而积累一个非常有价值且独特的手术和成像数据。 [1, 15, 16] 问题：该公司是医疗设备供应商；专有数据将由其客户（医院）生成，这可能会引入数据所有权和访问权限。
- Deep Qualification90
⚠ 需要审查 — Insight Medbotics 是一家医疗设备公司，而不是数据销售商；它开发和商业化MRI兼容的机器人系统。生成的数据是其设备临床使用过程中的副产品，这使得“医学影像数据集”的标签具有连贯性。数据所有权复杂，并且在严格的医疗法规下与临床合作伙伴共享。 [商业模式 = 工具供应商；许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
press
- “<p>ForSight Robotics' JASPER Platform assists surgeons with cataract surgeries, while still leaving the power in the surgeon's hands.</p> <p>The post <a href="https://www.therobotreport.com/forsight-robotics-road-to-performing-a-fully-robotic-cataracts-surgery/">ForSight Robotics’ road to performing a fully robotic cataract surgery</a> appeared first on <a href="https://www.therobotreport.com">The Robot Report</a>.</p>”
- “<p>With the acquisition of Robocath completed, Stereotaxis intends to accelerate development of next-generation robotic technologies for endovascular procedures.</p>”
- “<figure><div><img src="https://imgproxy.divecdn.com/d2JyuXgmLsPVrlZlLVlPLECICsiII5W1r34tQBQf49c/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjI3NzEwNTIwX0w2OGs1OEwuanBn.webp" /></div></figure><p>The draft agreement outlines the Food and Drug Administration’s goals for medical device reviews from 2028 to 2032.</p>”
IoT / sensor data
这表明持有者拥有来自机器人手术的精确时空数据，这对于训练机器人导航和自动化手术靶向的人工智能非常有价值。
Image collection
持有者拥有来自FDA批准的机器人平台的高分辨率MRI图像（最高3T），这是任何构建受监管的诊断人工智能工具的公司的高级资产。
Medical records / imaging
这指向来自MRI引导乳腺活检的临床研究的数据集，提供了黄金标准的、与结果相关的数据，对于证明模型有效性和安全性至关重要。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Insightmedbotics Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $1.8 billion in 2025, projected to grow at a CAGR of 35.1% (2026-2033) (source: Grand View Research). [1]. Investment score 68.8/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Clg Inc — 工业运营数据集机会
View opportunity →mobilityBroekmanlogistics — 工业运营数据集机会
View opportunity →工业Rocklink — 工业运营数据集机会
View opportunity →